Adial Pharmaceuticals ADILW 深 滬
等待開盤 11-12 09:30:00 美东时间
0.0009
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 總市值 1.58万
- 52周最高 0.199
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 總股本 1750.35万
- 歷史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adial Pharmaceuticals收涨36.12%，成交额46.29万美元
10月29日，Adial Pharmaceuticals（ADIL）收涨36.12%，报5.05美元，成交额46.29万美元，市值1326.08万美元。 行情数...
10-29 07:49
Azora Therapeutics Rebrands and Installs New Leadership Team
Adial Pharmaceuticals ( ($ADIL) ) just unveiled an announcement. On October 28,...
10-29 05:25
Adial Pharmaceuticals Expects To Appoint Celia Economides As CFO At Its Annual Meeting, Succeeding Vinay Shah
Ms. Economides brings more than two decades of experience in biotech finance, corporate development and capital markets. Over her career, she has helped execute more than $1 billion in equity financings, non-dilutive financings, and other strategic transactions. She joined Adial as Executive Vice Pr...
10-26 20:04
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals announced that Celia Economides, its current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer, succeeding Vinay Shah. Economides brings over two decades of experience in biotech finance, having raised over $1 billion in financings. She will lead the Company’s finance organization as it transitions to Azora Therapeutics and advances AT177 toward the clinic. Adial plans to change its nam...
10-26 12:00
Adial Pharmaceuticals收涨5.52%，成交额3.13万美元
10月21日，Adial Pharmaceuticals（ADIL）收涨5.52%，报3.82美元，成交额3.13万美元，市值1003.09万美元。 行情数据...
10-21 08:05
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing
Adial Pharmaceuticals ( ($ADIL) ) has shared an announcement. Adial Pharmaceuti...
10-17 05:51
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision
Adial Pharmaceuticals ( ($ADIL) ) has issued an announcement. Adial Pharmaceuti...
10-03 04:51
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals granted a stock option for 155,446 shares with an exercise price of $4.22, vesting over four years. The option was approved as an inducement for employment under Nasdaq rules. The company, now focused on inflammatory diseases, plans to advance AT177, an oral AhR agonist for ulcerative colitis, with IND filing and Phase 1 trials expected in 2027. Forward-looking statements are subject to risks and uncertainties.
09-30 21:46
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
Adial Pharmaceuticals ( ($ADIL) ) has shared an update. Adial Pharmaceuticals d...
09-17 05:29
Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On August 19, 2026, ...
08-26 04:57
